



NDA 50-821/S-004

SUPPLEMENT APPROVAL

B. Braun Medical, Inc.
Attention: Rebecca A. Stolarick
Corporate Vice President, Regulatory Affairs
901 Marcon Boulevard
Allentown, PA 18109

Dear Ms. Stolarick:

Please refer to your Supplemental New Drug Application (sNDA) dated August 26, 2015, received August 27, 2015, submitted under section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Cefepime for Injection, USP and Dextrose Injection, USP, Intravenous, 1g and 2g.

We also acknowledge receipt of your amendment dated November 2, 2015.

This “Changes Being Effected” supplemental new drug application provides for revisions to the **WARNINGS AND PRECAUTIONS**, Neurotoxicity (5.3) subsection, as well as the **ADVERSE REACTIONS**, Postmarketing Experience (6.2) subsection to add the term “aphasia”. In addition, the **PATIENT COUNSELING** section has been revised, along with other minor editorial revisions.

APPROVAL & LABELING

We have completed our review of this supplemental application and it is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(1)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at:

<http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>.

Content of labeling must be identical to the enclosed labeling, with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at:

<http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call J. Christopher Davi, MS, Senior Regulatory Project Manager, at (301) 796-0702.

Sincerely,

{See appended electronic signature page}

Sumathi Nambiar, MD, MPH
Director
Division of Anti-Infective Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

ENCLOSURE: Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

SUMATHI NAMBIAR
11/09/2015